Clinical Trials Logo

Central Precocious Puberty clinical trials

View clinical trials related to Central Precocious Puberty.

Filter by:

NCT ID: NCT02427958 Completed - Clinical trials for Central Precocious Puberty

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

Start date: August 7, 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess long-term safety and efficacy of leuprorelin in the treatment of Central Precocious Puberty (CPP).

NCT ID: NCT02006680 Terminated - Clinical trials for Central Precocious Puberty

Markers of Pubertal Suppression During Therapy for Precocious Puberty

Start date: December 2013
Phase:
Study type: Observational

The best way to measure whether treatment of children with central precocious puberty is working is to do a hormone stimulation test (leuprolide stimulation test) that requires injection of a medication and multiple blood draws to see if the hormonal response is suppressed (blocked). The hypothesis of this study is that random measurement of the free alpha subunit of pituitary glycoprotein, a protein related to the pituitary hormones that stimulate puberty, will provide an adequate alternative to the leuprolide stimulation testfor monitoring efficacy of pubertal suppression with Supprelin LA®.

NCT ID: NCT01634321 Completed - Clinical trials for Central Precocious Puberty

The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty

Start date: July 2011
Phase: Phase 4
Study type: Interventional

The purpose of this Clinical Trial was to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide acetate 3.75mg) in patients with precocious puberty.

NCT ID: NCT01467882 Completed - Clinical trials for Central Precocious Puberty

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Start date: April 2012
Phase: Phase 3
Study type: Interventional

The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).

NCT ID: NCT01278290 Completed - Clinical trials for Central Precocious Puberty

Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The aim of the study is to determine the specificity, sensitivity and diagnostic efficiency of the Triptorelin Test in the assessment of CPP compared to GnRH test as gold standard. Hypothesis: Aqueous Triptorelin Acetate is so efficient as GnRH to CPP assessment. Study population are girls with suspicious clinical features of precocious puberty

NCT ID: NCT00779103 Completed - Clinical trials for Central Precocious Puberty

Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to follow and collect additional medical and developmental information on children after histrelin subcutaneous implant therapy is discontinued.

NCT ID: NCT00438217 Recruiting - Clinical trials for Central Precocious Puberty

Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children

CPP-EDG 01
Start date: n/a
Phase: Phase 4
Study type: Interventional

The goal of CPP-EDG 01 study is to assess possible genetic and/or environmental parameters which may influence the growth rate of children affected by precocious puberty. In this view, we are collecting clinical data and biological samples of children attended as outpatients at the Pediatric Endocrine Center of Pisa from 1998 to present (the study is still open). From biological (blood) samples, gene polymorphisms such as endocrine disruptor levels are determined and compared to different growth pattern of pediatric patients treated with different GnRH agonists.